Disease · MONDO_0006951
Comparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 20
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active vs Control: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) | 114 of 231 | 127 of 229 | 460 | NCT02980874 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 231 | 0 of 229 | 460 | NCT02980874 | Trial comparisons |
| Active vs Control: serious adverse events | 25 of 231 | 28 of 229 | 460 | NCT02980874 | Trial comparisons |
| Aflibercept vs Bevacizumab: deaths from any cause | 1 of 180 | 1 of 182 | 362 | NCT01969708 | Trial comparisons |
| Aflibercept vs Bevacizumab: serious adverse events | 14 of 180 | 14 of 182 | 362 | NCT01969708 | Trial comparisons |
| Active vs Control: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) | 64 of 162 | 76 of 163 | 325 | NCT03203447 | Trial comparisons |
| Active vs Control: deaths from any cause | 0 of 160 | 0 of 162 | 322 | NCT03203447 | Trial comparisons |
| Active vs Control: serious adverse events | 1 of 160 | 3 of 162 | 322 | NCT03203447 | Trial comparisons |
| Patients With RVO vs Patients With DME: serious adverse events | 12 of 165 | 12 of 156 | 321 | NCT01918371 | Trial comparisons |
| Ranibizumab vs Dexamethasone: Rate of the Internal Ocular Pressure (IOP) | 79 of 126 | 106 of 118 | 244 | NCT01396057 | Trial comparisons |
| Ranibizumab vs Dexamethasone: serious adverse events | 7 of 126 | 9 of 118 | 244 | NCT01396057 | Trial comparisons |
| Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): serious adverse events | 10 of 92 | 13 of 91 | 183 | NCT01521559 | Trial comparisons |
Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF | 24 of 90 | 48 of 91 | 181 | NCT01521559 | Trial comparisons |
| Topical Anesthesia vs Subconjunctival Anesthesia: serious adverse events | 0 of 57 | 0 of 57 | 114 | NCT01640171 | Trial comparisons |
| Suprachoroidal CLS-TA + IVT Aflibercept vs Suprachoroidal Sham + IVT Aflibercept: deaths from any cause | 0 of 23 | 0 of 23 | 46 | NCT02303184 | Trial comparisons |
| Suprachoroidal CLS-TA + IVT Aflibercept vs Suprachoroidal Sham + IVT Aflibercept: serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT02303184 | Trial comparisons |
| KPI-121 1.0% Ophthalmic Suspension vs KPI-121 0.25% Ophthalmic Suspension: serious adverse events | 0 of 9 | 1 of 7 | 16 | NCT02245516 | Trial comparisons |
| Peripheral Laser + Ranibizumab vs Ranibizumab: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT01247220 | Trial comparisons |
| Ozurdex PRN vs Ozurdex Q16 Weeks: deaths from any cause | 0 of 5 | 1 of 5 | 10 | NCT01449682 | Trial comparisons |
| Ozurdex PRN vs Ozurdex Q16 Weeks: serious adverse events | 1 of 5 | 0 of 5 | 10 | NCT01449682 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006951/comparisons